Journal: eClinicalMedicine

Article Title: Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

doi: 10.1016/j.eclinm.2026.103767

Figure Lengend Snippet: Participant dispositions and analysis populations . a One participant did not complete the 1-month postvaccination visit but completed the end-of-study telephone call. b The end-of-study telephone call was scheduled to take place 42–49 days after vaccination. c Participants could be excluded for more than one reason. MDV = multidose vial; RSVpreF = respiratory syncytial virus prefusion F protein vaccine; SDV = single-dose vial.

Article Snippet: Multiple phase 3 clinical trials have demonstrated safety, immunogenicity, and efficacy of the bivalent RSV prefusion F protein unadjuvanted vaccine (RSVpreF; Abrysvo®; Pfizer Inc, New York, NY, USA), leading to US approval in 2023. , , , , In the placebo-controlled phase 3 Maternal Immunization Study for Safety and Efficacy (MATISSE), efficacy rates of RSVpreF vaccination against severe RSV-associated medically attended lower respiratory tract illness among infants born to pregnant women who received 120 μg RSVpreF at 24–36 weeks’ gestation were 82·4% and 70·0% within 90 and 180 days after birth, respectively.

Techniques: Virus

Journal: eClinicalMedicine

Article Title: Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

doi: 10.1016/j.eclinm.2026.103767

Figure Lengend Snippet: (a) RSV neutralising GMRs of the RSVpreF MDV group to the RSVpreF SDV group at 1 month after vaccination and corresponding GMTs and GMFRs from baseline for (b) RSV A and (c) RSV B . Data are for the evaluable immunogenicity population. Error bars represent 95% CIs. Dotted line indicates prespecified noninferiority acceptance criteria for the lower limit of the 95% CIs. If the titre before vaccination was

Article Snippet: Multiple phase 3 clinical trials have demonstrated safety, immunogenicity, and efficacy of the bivalent RSV prefusion F protein unadjuvanted vaccine (RSVpreF; Abrysvo®; Pfizer Inc, New York, NY, USA), leading to US approval in 2023. , , , , In the placebo-controlled phase 3 Maternal Immunization Study for Safety and Efficacy (MATISSE), efficacy rates of RSVpreF vaccination against severe RSV-associated medically attended lower respiratory tract illness among infants born to pregnant women who received 120 μg RSVpreF at 24–36 weeks’ gestation were 82·4% and 70·0% within 90 and 180 days after birth, respectively.

Techniques: Immunopeptidomics, Transformation Assay, Quantitation Assay, Virus

Journal: eClinicalMedicine

Article Title: Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

doi: 10.1016/j.eclinm.2026.103767

Figure Lengend Snippet: Rates of (a) local reactions and (b) systemic events reported within 7 days after vaccination . Data are for the safety population. Error bars represent 95% CIs, which were calculated using the Clopper-Pearson method. The number of participants included in each group was as follows: RSVpreF MDV, n = 223; RSVpreF SDV, n = 227. Grading scales are provided in . MDV = multidose vial; RSVpreF = respiratory syncytial virus prefusion F protein vaccine; SDV = single-dose vial.

Article Snippet: Multiple phase 3 clinical trials have demonstrated safety, immunogenicity, and efficacy of the bivalent RSV prefusion F protein unadjuvanted vaccine (RSVpreF; Abrysvo®; Pfizer Inc, New York, NY, USA), leading to US approval in 2023. , , , , In the placebo-controlled phase 3 Maternal Immunization Study for Safety and Efficacy (MATISSE), efficacy rates of RSVpreF vaccination against severe RSV-associated medically attended lower respiratory tract illness among infants born to pregnant women who received 120 μg RSVpreF at 24–36 weeks’ gestation were 82·4% and 70·0% within 90 and 180 days after birth, respectively.

Techniques: Virus

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season

doi: 10.1093/cid/ciaf496

Figure Lengend Snippet: Study population flowchart, Kaiser Permanente Southern California (KPSC)—November 2023 to April 2024. Samples that were not tested for respiratory syncytial virus (RSV) include nonsalvageable point-of-care swab samples and samples positive for influenza or severe acute respiratory syndrome coronavirus 2 that were not salvaged for RSV testing. The RSV-unvaccinated patients from nonstudy sites include those with emergency department (ED)/hospitalization events at KPSC in which RSV testing was conducted and the RSVpreF vaccine was not available for a population meeting eligibility criteria. Abbreviations: ARI, acute respiratory illness; LRTD, lower respiratory tract disease; SOC, standard-of-care.

Article Snippet: Previously, we showed that the RSVpreF vaccine (Abrysvo; Pfizer) prevents RSV-related lower respiratory tract disease–related emergency department (ED) visits/hospitalizations in older adults.

Techniques: Virus

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season

doi: 10.1093/cid/ciaf496

Figure Lengend Snippet: Vaccine effectiveness (VE; with 95% confidence interval [CI]) of the RSVpreF vaccine against respiratory syncytial virus (RSV)–related acute respiratory illness (ARI) hospital and/or emergency department (ED) encounters, by select outcome—Kaiser Permanente Southern California, November 2023 to April 2024. a VE was adjusted for age, sex, encounter months, race/ethnicity, Charlson Comorbidity Index, and previous outpatient, inpatient encounters, and ED encounters. b In the strict analysis, case patients were positive for RSV. Controls were positive for a non–vaccine-preventable disease (VPD) and negative for RSV, human metapneumovirus, and VPDs. c In the broad analysis, case patients were positive for RSV, and controls included all who were negative for RSV. d Severe ARI was defined as that requiring supplemental oxygen use. e High-risk ARI was ARI among those with high-risk chronic medical conditions, including asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease, other chronic lung, cardiac, renal, and liver diseases, diabetes mellitus, neurologic conditions, stroke, autoimmune disorders, immunocompromising conditions and medications, human immunodeficiency virus, AIDS, cancers, organ transplant and blood disorders. f Critical outcomes include intensive care unit admission, mechanical ventilation, respiratory failure, vasopressor use, and death.

Article Snippet: Previously, we showed that the RSVpreF vaccine (Abrysvo; Pfizer) prevents RSV-related lower respiratory tract disease–related emergency department (ED) visits/hospitalizations in older adults.

Techniques: Virus, Medications

Journal: Cureus

Article Title: Preventing Respiratory Syncytial Virus in Infants: A Comparative Review of Nirsevimab and Maternal Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination

doi: 10.7759/cureus.94483

Figure Lengend Snippet: Maternal RSVpreF vaccination administered during 24-36 weeks of gestation induces maternal antibody production with transplacental transfer to the infant, conferring protection for up to six months. Nirsevimab, a long-acting monoclonal antibody administered directly to the infant, provides protection for approximately five months (one RSV season). GA = gestational age; RSV = respiratory syncytial virus.

Article Snippet: The development of two novel immunoprophylactic strategies has transformed the prevention landscape: nirsevimab, a long-acting monoclonal antibody administered directly to infants, and the maternal respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo, Pfizer Inc., New York, NY), which induces maternal antibodies that cross the placenta and protect newborns.

Techniques: Virus